Gildan/HanesBrands: Paperwork Pulled and Refiled, Giving FTC More Time to Conduct Initial Review

Gildan Activewear (GIL) pulled and refiled the HSR form for its planned acquisition of HanesBrands (HBI), according to a company spokesperson, giving the FTC 30 additional days to conduct an initial review of the $2.2 billion deal. The companies initially filed their HSR forms on September 18. Gildan withdrew its application yesterday and refiled today, […]

Medline: In Rare Move, FDA Revokes Regulatory Approval for Several Medical Devices Sold by Company

The FDA has revoked the regulatory approvals for several medical devices sold by Medline (MDLN), according to recent updates on the agency’s recall database. 22 Medline devices and kits are being...

Apr 24, 2026 Read Now >

House Judiciary Panel Counsel Cella, Paul Hastings Partner Murray Emerge as Early Contenders to Become DOJ Antitrust Head

Adam Cella, a senior House GOP counsel, and Michael Murray, who served at DOJ during President Donald Trump’s first term, have emerged as early contenders to take over the department’s antitrust...

Apr 20, 2026 Read Now >

Private Equity Investment in Clinical Trial Sites Raises Potential Antitrust, CPOM Concerns

Private equity’s growing interest in clinical trial sites and services raises questions about how increased consolidation will impact the cost and sustainability of pharmaceutical research and...

Apr 17, 2026 Read Now >

Gildan/HanesBrands: Paperwork Pulled and Refiled, Giving FTC More Time to Conduct Initial Review

RELATED ARTICLES | Editor’s picks

Medline: In Rare Move, FDA Revokes Regulatory Approval for Several Medical Devices Sold by Company

House Judiciary Panel Counsel Cella, Paul Hastings Partner Murray Emerge as Early Contenders to Become DOJ Antitrust Head

Private Equity Investment in Clinical Trial Sites Raises Potential Antitrust, CPOM Concerns

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.